Back to top

Analyst Blog

MannKind Corporation (MNKD - Analyst Report) recently entered into a Facility Agreement with investment management firm Deerfield Management Company L.P. (Deerfield). As per the agreement, MannKind has ensured financing worth $160 million from Deerfield. Deerfield has agreed to provide the loan through its purchase of four equal tranches of senior secured notes from MannKind. The notes, due to mature in 2019, will carry a yearly interest of 9.75%.

Deerfield will be paying the first of the four $40 million tranches following the closure of the deal. The next tranche will be received following the announcement of certain results from MannKind’s two phase III studies (Study 171 and Study 175) on its diabetes candidate Afrezza. MannKind is expected to receive its third tranche on the repayment of its 3.75% Senior Convertible Notes due 2013.

The last and final payment will be received on approval of Afrezza. MannKind further stated in its press release that a portion of the loan amount can be converted to shares of its common stock after a specified time following the publication of data from the Afrezza studies. As per the agreement, Deerfield received milestone rights from MannKind. Deerfield will receive up to $90 million on the achievement of some strategic and sales milestones.

MannKind is yet to decide the conversion price, which will be decided by the volume weighted average price of the common stock during the next 20 trading days following the conversion date. MannKind stated that less than 6 million shares will be issued on conversion if the conversion price is more than $6.67.

Moreover, less than 12 million shares will be issued on conversion if the price is below $3.33. MannKind also mentioned that if the conversion price is between $3.33 and $6.67, not more than $40 million of common stock will be issued on conversion.

We are encouraged by MannKind’s efforts to raise funds. We expect the company utilise the amount raised on Afrezza. MannKind is totally dependent on the success of the diabetes candidate.

Meanwhile, MannKind completed both the phase III studies (Study 171 and Study 175) on Afrezza. MannKind intends to resubmit the New Drug Application to the FDA for Afrezza in late September or early October this year. MannKind intends to get Afrezza approved for treating adults suffering from type 1 or type 2 diabetes. We expect investor focus to remain on Afrezza going forward.

MannKind, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Other biopharma stocks, such as Jazz Pharmaceuticals (JAZZ - Analyst Report), Santarus, Inc. and Cadence Pharmaceuticals Inc. are comparatively well placed. While Jazz Pharma and Santarus carry a Zacks Rank #1 (Strong Buy), Cadence carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%